We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.54B
1-Year Est. Return 86.39%
This Fund
S&P 500
This Quarter Est. Return
-5.41%
1 Year Est. Return
+86.39%
3 Year Est. Return
-13.28%
5 Year Est. Return
-50.7%
10 Year Est. Return
+414.55%
AUM
$284M
AUM Growth
-$92.7M
Cap. Flow
-$71.1M
Cap. Flow %
-25.08%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
–
Closed
3

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$56.4M
2
RNAC icon
Cartesian Therapeutics
RNAC
+$11.8M
3
CARM
Carisma Therapeutics
CARM
+$2.91M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCRB icon
1
Seres Therapeutics
MCRB
$46.2M
$143M 50.54%
634,144
– –
SYRS
2
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$77.3M 27.27%
480,666
– –
EDIT icon
3
Editas Medicine
EDIT
$404M
$56.7M 19.98%
3,376,184
– –
TTOO
4
DELISTED
T2 Biosystems, Inc
TTOO
$6.26M 2.21%
390
– –
AGIO icon
5
Agios Pharmaceuticals
AGIO
$1.96B
– –
-965,369
Closed -$56.4M
CARM
6
DELISTED
Carisma Therapeutics
CARM
– –
-66,201
Closed -$2.91M
RNAC icon
7
Cartesian Therapeutics
RNAC
$239M
– –
-27,562
Closed -$11.8M

Similar funds

SPC
Stony Point Capital New York $1.54B AUM 54.05% 1-Year Est. Return
AWC
Abundance Wealth Counselors State College, Pennsylvania $1.54B AUM 31.07% 1-Year Est. Return
SMC
Smith, Moore & Co Clayton, Missouri $1.54B AUM 24.82% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.54B AUM 30.95% 1-Year Est. Return
BOF
Bank of Finland Helsinki, Finland $1.54B AUM 15.84% 1-Year Est. Return
KCM
Kanawha Capital Management Richmond, Virginia $1.54B AUM 21.3% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.54B AUM 27.61% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $1.54B AUM 30.1% 1-Year Est. Return

Flagship Pioneering's Q2 2017 Portfolio in Review

As of Q2 2017, Flagship Pioneering held 7 positions worth $284M, down 25% from $376M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Flagship Pioneering withdrew a net $71.1M in Q2 2017, closing 3 positions. Its most notable exit was Agios Pharmaceuticals, an estimated $56.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Flagship Pioneering fully exited Agios Pharmaceuticals in Q2 2017, selling an estimated $56.4M.
  • Flagship Pioneering's ten largest holdings make up 100% of its $284M portfolio in Q2 2017.
  • Flagship Pioneering opened 0 new positions and closed 3 in Q2 2017.
  • Flagship Pioneering's portfolio value fell 25% quarter-over-quarter to $284M.

Based on Flagship Pioneering's 13F filing for Q2 2017, filed 2 Aug 2017.